drugset / Trial / NCT00513305
Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to determine whether low-dose cytarabine in combination with arsenic trioxide is more effective than low-dose cytarabine alone in achieving complete remission in elderly patients (≥60 years of age) with acute myeloid leukemia.
Timeline
- Start
- 2007-10
- Primary completion
- 2009-07
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cytarabine | Small molecule | 10 mg/m2 | Subcutaneous |
| Comparator | arsenic trioxide | Small molecule | 0.25 mg/kg | Intravenous |